Home » Authors » Kim Coghill

Kim Coghill

Articles

ARTICLES

Rigel's Stock Leaps On R112 Phase II Allergic Rhinitis Data

Aug. 3, 2004

OSI, Genentech Submit NDA For Tarceva As Therapy For NSCLC

Aug. 3, 2004

OSI Pharmaceuticals Inc. and partner Genentech Inc. completed the submission of a new drug application for Tarceva, a drug for the treatment of patients with advanced non-small-cell lung cancer who have failed chemotherapy. (BioWorld Today)

OSI, Genentech Submit NDA For Tarceva As Therapy For NSCLC

Aug. 3, 2004

OSI Pharmaceuticals Inc. and partner Genentech Inc. completed the submission of a new drug application for Tarceva, a drug for the treatment of patients with advanced non-small-cell lung cancer who have failed chemotherapy. (BioWorld Today)

Rigel's Stock Leaps On R112 Phase II Allergic Rhinitis Data

Aug. 3, 2004

NAS Report On GM Foods Welcomed By Industry, BIO

Aug. 2, 2004

NAS Report On GM Foods Welcomed By Industry, BIO

Aug. 2, 2004

Unable To Afford Drug Discovery, Sequenom Focusing On Services

July 30, 2004

Unable To Afford Drug Discovery, Sequenom Focusing On Services

July 30, 2004

Lexicon, Takeda In Agreement For High Blood Pressure Drugs

July 29, 2004

Lexicon, Takeda In Agreement For High Blood Pressure Drugs

July 29, 2004

View All Articles by Kim Coghill

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...